|
Valoración de DCF de Evogene Ltd. (EVGN)
IL | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Evogene Ltd. (EVGN) Bundle
¡Agilice su análisis y aumente la precisión con nuestra calculadora DCF (EVGN)! Utilizando datos auténticos de Evogene Ltd. y supuestos personalizables, esta herramienta le permite pronosticar, analizar y valor (EVGN) como un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .8 | 1.0 | .9 | 1.7 | 5.6 | 8.6 | 13.0 | 19.8 | 30.0 | 45.6 |
| Revenue Growth, % | 0 | 38.11 | -10.58 | 80.11 | 236.72 | 51.91 | 51.91 | 51.91 | 51.91 | 51.91 |
| EBITDA | -16.0 | -23.2 | -27.8 | -26.9 | -23.2 | -8.6 | -13.0 | -19.8 | -30.0 | -45.6 |
| EBITDA, % | -2120.58 | -2228.65 | -2988.71 | -1607.94 | -411.42 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 2.8 | 2.7 | 2.2 | 2.6 | 2.6 | 7.6 | 11.6 | 17.6 | 26.8 | 40.7 |
| Depreciation, % | 367.73 | 262.21 | 240.22 | 154.03 | 46.31 | 89.26 | 89.26 | 89.26 | 89.26 | 89.26 |
| EBIT | -18.7 | -25.9 | -30.0 | -29.5 | -25.8 | -8.6 | -13.0 | -19.8 | -30.0 | -45.6 |
| EBIT, % | -2488.31 | -2490.87 | -3228.92 | -1761.97 | -457.73 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 46.9 | 48.2 | 53.9 | 35.4 | 31.1 | 8.6 | 13.0 | 19.8 | 30.0 | 45.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.2 | 2.2 | 1.2 | .8 | .7 | 6.2 | 9.4 | 14.2 | 21.6 | 32.8 |
| Account Receivables, % | 160.69 | 208.46 | 126.24 | 47.94 | 11.9 | 71.97 | 71.97 | 71.97 | 71.97 | 71.97 |
| Inventories | -.9 | -1.4 | .1 | .6 | .1 | -2.7 | -4.0 | -6.1 | -9.3 | -14.1 |
| Inventories, % | -118.73 | -132.6 | 9.89 | 33.79 | 1.35 | -30.99 | -30.99 | -30.99 | -30.99 | -30.99 |
| Accounts Payable | 1.0 | .9 | 1.5 | 1.0 | 1.8 | 6.5 | 9.8 | 14.9 | 22.6 | 34.4 |
| Accounts Payable, % | 132.93 | 82.98 | 157.31 | 61.85 | 31.65 | 75.3 | 75.3 | 75.3 | 75.3 | 75.3 |
| Capital Expenditure | -.9 | -.7 | -.7 | -1.2 | -.8 | -5.6 | -8.5 | -12.9 | -19.7 | -29.9 |
| Capital Expenditure, % | -119.52 | -65.58 | -77.85 | -69.91 | -13.92 | -65.45 | -65.45 | -65.45 | -65.45 | -65.45 |
| Tax Rate, % | 8.11 | 8.11 | 8.11 | 8.11 | 8.11 | 8.11 | 8.11 | 8.11 | 8.11 | 8.11 |
| EBITAT | -17.8 | -23.1 | -27.4 | -26.4 | -23.7 | -7.8 | -11.9 | -18.1 | -27.4 | -41.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -15.2 | -21.7 | -25.8 | -25.5 | -20.5 | -3.9 | -7.3 | -11.0 | -16.8 | -25.5 |
| WACC, % | 6.34 | 6.19 | 6.24 | 6.19 | 6.26 | 6.24 | 6.24 | 6.24 | 6.24 | 6.24 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -51.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -26 | |||||||||
| Terminal Value | -612 | |||||||||
| Present Terminal Value | -452 | |||||||||
| Enterprise Value | -504 | |||||||||
| Net Debt | -9 | |||||||||
| Equity Value | -494 | |||||||||
| Diluted Shares Outstanding, MM | 5 | |||||||||
| Equity Value Per Share | -108.23 |
What You Will Receive
- Pre-Filled Financial Model: Evogene Ltd.’s actual data facilitates accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates provide immediate feedback as you adjust inputs.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
- Customizable and Reusable: Designed for adaptability, allowing for multiple applications in detailed forecasting.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Evogene Ltd. (EVGN).
- WACC Analysis Tool: Features a pre-configured Weighted Average Cost of Capital sheet with adjustable parameters.
- Customizable Forecast Inputs: Adjust growth projections, capital expenditures, and discount rates as needed.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for Evogene Ltd. (EVGN).
- Interactive Dashboard and Visuals: Graphical representations highlight essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Evogene Ltd. (EVGN) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Evogene Ltd.'s (EVGN) intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Evogene Ltd. (EVGN)?
- Designed for Experts: A sophisticated tool tailored for biotech analysts, investors, and researchers.
- Comprehensive Data: Evogene’s historical and projected financials are preloaded for precision.
- Flexible Modeling: Easily test various scenarios and assumptions to gauge potential outcomes.
- Insightful Results: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience throughout the process.
Who Should Use This Product?
- Investors: Accurately assess Evogene Ltd.'s (EVGN) fair value to inform investment choices.
- CFOs: Utilize a professional-grade DCF model for comprehensive financial reporting and analysis.
- Consultants: Easily customize the template for client valuation reports related to Evogene Ltd. (EVGN).
- Entrepreneurs: Discover financial modeling techniques employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies in the biotech sector.
What the Template Contains
- Pre-Filled DCF Model: Evogene Ltd.’s (EVGN) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Evogene Ltd.’s (EVGN) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.